KR920701207A - 신규 키산틴 유도체 - Google Patents

신규 키산틴 유도체

Info

Publication number
KR920701207A
KR920701207A KR1019910700878A KR910700878A KR920701207A KR 920701207 A KR920701207 A KR 920701207A KR 1019910700878 A KR1019910700878 A KR 1019910700878A KR 910700878 A KR910700878 A KR 910700878A KR 920701207 A KR920701207 A KR 920701207A
Authority
KR
South Korea
Prior art keywords
compound
chianthine
amino
hydrogen
butyl
Prior art date
Application number
KR1019910700878A
Other languages
English (en)
Other versions
KR970001528B1 (ko
Inventor
더블유 그리스트우드 로버트
베가 노베롤라 아만도
마누엘 프로에토 소토 요세
모라구에스 마우리 야신토
Original Assignee
원본미기재
레버리토리오스 알미랄 소시에다 아노니마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 레버리토리오스 알미랄 소시에다 아노니마 filed Critical 원본미기재
Publication of KR920701207A publication Critical patent/KR920701207A/ko
Application granted granted Critical
Publication of KR970001528B1 publication Critical patent/KR970001528B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

신규 키산틴 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 일반식:
    Ⅰ
    의 화합물, 및 유기염기를 함유하는 질소염기 또는 알칼리 금속 염기와의 이 화합물의 약리학적 허용 염.
    상기식에서 R1은 3내지 6탄소원자의 직쇄 또는 분기쇄 알킬, 알케닐 또는 알키닐이고, R2및 R3는 같거나 다를수 있고 각각은 수소 또는 할로겐 또는 메틸, 메톡시, 니트로 또는 트리플루오로메틸기이고 R2와 R3는 함께 메틸렌디옥시 또는 에틸렌디옥시기를 형성하고, 단 R2와 R3는 둘다 수소는 아니다.
  2. 제1항에 있어서, R1은 n-프로필, 이소-프로필, n-부틸, 이소-부틸, tert-부틸 또는 n-헥실기인 것을 특징으로 하는 화합물.
  3. 제1항 또는 제2항에 있어서, R2및R3는 같거나 다를수 있고 각각은 H, F, CL, Br 또는 메톡시이고 R2및 R3는 함께 메틸렌디옥시인 것을 특징으로 하는 화합물.
  4. 제1항에 있어서, 1-n-프로필-3-(4-클로로페닐)-키산틴, 1-n-프로필-3-(3,4-클로로페닐)-키산틴, 1-n-부틸-3-(3-니트로페닐)-키산틴, 1-n-부틸-3-(3-메톡시페닐)-키산틴, 또는 1-n-헥실-3-(3,4-메틸렌디옥시페닐)-키산틴인 것을 특징으로 하는 화합물.
  5. 일반식:
    Ⅳ
    의 5,6-디아민(상기식에서 R1, R2및 R3는 상기에서 정의된 바와 같다)을 포름아미드와 반응시켜 이루어지는 것을 특징으로 하는, 일반식:
    Ⅰ
    의 화합물 및 유기 염기를 함유하는 질소염기 또는 알칼리 금속 염기와의 이 화합물의 약리학적 허용 염의 제조방법.
    상기식에서 R1은 3내지 6탄소원자의 직쇄 또는 분기쇄 알킬, 알케닐 또는 알키닐이고, R2및 R3는 같거나 다를수 있고 각각은 수소 또는 할로겐 또는 메틸, 메톡시, 니트로 또는 트리플루오로메틸기이고 또는 R2와 R3는 함께 메틸렌디옥시 또는 에텔렌디옥시기를 형성하고, 단 R2와 R3는 둘다 수소는 아니다.
  6. 재5항에 있어서, 5,6-디아민은 일반식:
    Ⅲ
    의 6-아미노-5-니트로소 화합물을 환원시켜 제조되는 것을 특징으로 하는 방법.
  7. 제6항에 있어서, 6-아미노-5-니트로소 화합물은 일반식:
    Ⅱ
    의 6-아미노-우라실을 니트로소화시켜 제조되는 것을 특징으로 하는 방법.
  8. 제5항 내지 제7항에 있어서, 6-아미노-5-니트로소 화합물 및 5,6-디아민은 인-시튜(in situ)로 제조되는 것을 특징으로 하는 방법.
  9. 제8항에 있어서, 식 Ⅱ의 6-아미노-키산틴은 반응혼합물에 첨가된 과량의 포름아미드 및 디티오나이트 나트륨의 존재하에서 포름산 및 아질산 나트륨과 반응시여 생성 6-아미노-5-니트로소 화합물을 환원시키는 것을 특징으로 하는 방법.
  10. 제5항 내지 제9항중의 어느 한 항에 있어서, 식 Ⅰ의 생성 키산틴은 유기염기를 함유하는 질소 또는 알칼리 금속과의 염 형태로 단리되는 것을 특징으로 하는 방법.
  11. 약학적 어용 담체 또는 희석제와 함께 제1항 내지 제4항중의 어느 한 항에 정의된 일반식 Ⅰ의 키산틴 또는 그 염을 함유하는 약학적 조성물.
  12. 인체 또는 동물의 치료방법에 사용되는 것을 특징으로 하는 제1항 내지 제4항중 어느 한 항에 정의된 키산틴 또는 그 염.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700878A 1989-12-27 1990-12-27 신규 키산틴 유도체 KR970001528B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898929208A GB8929208D0 (en) 1989-12-27 1989-12-27 New xanthine derivatives
GB8929208.0 1989-12-27
PCT/GB1990/002027 WO1991009859A1 (en) 1989-12-27 1990-12-27 New xanthine derivatives

Publications (2)

Publication Number Publication Date
KR920701207A true KR920701207A (ko) 1992-08-11
KR970001528B1 KR970001528B1 (ko) 1997-02-11

Family

ID=10668520

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700878A KR970001528B1 (ko) 1989-12-27 1990-12-27 신규 키산틴 유도체

Country Status (30)

Country Link
US (1) US5223504A (ko)
EP (1) EP0435811B1 (ko)
JP (1) JPH089617B2 (ko)
KR (1) KR970001528B1 (ko)
CN (1) CN1029967C (ko)
AT (1) ATE93860T1 (ko)
AU (1) AU635104B2 (ko)
BR (1) BR9007258A (ko)
CA (1) CA2045478C (ko)
CZ (1) CZ278328B6 (ko)
DE (1) DE69003087T2 (ko)
DK (1) DK0435811T3 (ko)
EG (1) EG19436A (ko)
ES (1) ES2058864T3 (ko)
FI (1) FI96207C (ko)
GB (1) GB8929208D0 (ko)
HU (2) HU208825B (ko)
IE (1) IE64065B1 (ko)
IL (1) IL96708A (ko)
MX (1) MX23884A (ko)
MY (1) MY105303A (ko)
NO (1) NO178111C (ko)
NZ (1) NZ236517A (ko)
PL (1) PL166152B1 (ko)
PT (1) PT96332B (ko)
RU (1) RU2073679C1 (ko)
SK (1) SK278365B6 (ko)
UA (1) UA32512C2 (ko)
WO (1) WO1991009859A1 (ko)
ZA (1) ZA9010240B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
ATE247116T1 (de) 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
CA2206804C (en) 1994-12-13 2002-03-19 Euro-Celtique, S.A. Trisubstituted thioxanthines
JPH11505241A (ja) * 1995-05-19 1999-05-18 カイロサイエンス・リミテッド キサンチン類およびこれらの治療的使用
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU722480B2 (en) * 1996-11-01 2000-08-03 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
CA2372850C (en) * 1999-05-04 2011-01-18 Ulrich Kilian Synergistic combination comprising roflumilast and a pde-3 inhibitor
KR100701904B1 (ko) 1999-08-21 2007-04-02 알타나 파마 아게 Ｐｄｅ 억제제 및 베타 2 아드레날린수용체 작동제의상승적 조합
GB0005199D0 (en) * 2000-03-04 2000-04-26 Imp College Innovations Ltd Modulation of histone deacetylase
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
JP4510383B2 (ja) * 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103764672A (zh) 2011-03-01 2014-04-30 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
AR115689A1 (es) 2018-07-05 2021-02-17 Sumitomo Chemical Co Compuestos de uracilo y su utilización
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
CH629788A5 (de) * 1977-07-20 1982-05-14 Lonza Ag Verfahren zur herstellung von 5,6-diaminouracil.
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds

Also Published As

Publication number Publication date
MY105303A (en) 1994-09-30
HUT57766A (en) 1991-12-30
DK0435811T3 (da) 1993-11-01
CA2045478A1 (en) 1991-06-28
ATE93860T1 (de) 1993-09-15
WO1991009859A1 (en) 1991-07-11
NO913236L (no) 1991-08-19
FI914014A0 (fi) 1991-08-26
CN1029967C (zh) 1995-10-11
FI96207C (fi) 1996-05-27
NO178111C (no) 1996-01-24
MX23884A (es) 1993-09-01
US5223504A (en) 1993-06-29
NO178111B (no) 1995-10-16
SK278365B6 (en) 1997-01-08
HU208825B (en) 1994-01-28
PL166152B1 (en) 1995-04-28
JPH05500226A (ja) 1993-01-21
BR9007258A (pt) 1992-02-25
CZ278328B6 (en) 1993-11-17
IL96708A0 (en) 1991-09-16
IE64065B1 (en) 1995-07-12
FI96207B (fi) 1996-02-15
IL96708A (en) 1994-06-24
NZ236517A (en) 1992-09-25
EP0435811A1 (en) 1991-07-03
IE904634A1 (en) 1991-07-17
HU211573A9 (en) 1995-12-28
AU6976891A (en) 1991-07-24
UA32512C2 (uk) 2001-02-15
JPH089617B2 (ja) 1996-01-31
CN1052858A (zh) 1991-07-10
DE69003087D1 (de) 1993-10-07
PT96332A (pt) 1991-09-30
GB8929208D0 (en) 1990-02-28
RU2073679C1 (ru) 1997-02-20
NO913236D0 (no) 1991-08-19
AU635104B2 (en) 1993-03-11
KR970001528B1 (ko) 1997-02-11
EP0435811B1 (en) 1993-09-01
ES2058864T3 (es) 1994-11-01
ZA9010240B (en) 1991-10-30
EG19436A (en) 1995-02-28
DE69003087T2 (de) 1993-12-16
PT96332B (pt) 1998-06-30
CA2045478C (en) 1998-12-29

Similar Documents

Publication Publication Date Title
KR920701207A (ko) 신규 키산틴 유도체
YU208687A (en) Process for obtaining analog of rebecamicine
US4299832A (en) Substituted theophylline compounds
HUT59081A (en) Process for producing aryl- and heteroaryl-ethylene derivatives and pharmaceutical compositions containing them
BG60270B1 (bg) Метод за получаване на 5н-2,3-бензодиазепинови производни
PT787726E (pt) Novo composto, processo para a sua producao e agente tumoral
KR890011904A (ko) 안드로스타-1,4, -디엔-3,17-디온의 6-메틸렌 유도체 합성방법
US4736029A (en) Process for preparing 2-amino-6-chloropurine
EP0068407A1 (en) Aminosulfonylbenzoic acid derivatives
KR920021530A (ko) 2-아미노-5-시아노-1,4-디히드로피리딘, 그의 제조방법 및 약제로서의 그의 용도
US4157340A (en) N,N'-[Bis(N-cyanoguanyl)]cystamine derivatives
HUT40793A (en) Process for preparing hexene-carboxylic acid derivatives
DE68928127D1 (de) 2'-Methylidenpyrimidinnukleosidverbindungen, ihre Verwendung und Verfahren zu ihrer Herstellung
YU45392B (en) Process for obtaining derivatives of 1-methylamino-quinoline-carboxilic acid
GB1490162A (en) (1-alkyl-5-nitro-imidazolyl-2-alkyl)-heteroaryl compounds and process for their manufacture
KR840001286B1 (ko) 2-이미다졸린 유도체류의 제조방법
SU1616912A1 (ru) Способ получени 5(6)-бромпроизводных бензимидазола
YU45822B (sh) Postupak za dobijanje supstituisanih etandimidamida
TH7749EX (th) อนุพันธ์ไธอีโน (3,4-4,5) อิมิดาโซ (2,1-บี) ไธอะโซลต่าง ๆต่าง ๆ กระบวนการสำหรับการผลิตและการใช้ประโยชน์ทางยา
KR890002153A (ko) 2-티아졸일-이미다조[1,2-a]피리미딘, 이들의 염,이들의 제조방법, 약제로서 이들의 용도 및 이들 화합물을 함유하는 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070723

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee